dc.creator | Rouka E., Livanou E., Sinis S., Dimeas I., Pantazopoulos I., Papagiannis D., Malli F., Kotsiou O., Gourgoulianis K.I. | en |
dc.date.accessioned | 2023-01-31T09:51:55Z | |
dc.date.available | 2023-01-31T09:51:55Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.1111/jdi.13787 | |
dc.identifier.issn | 20401116 | |
dc.identifier.uri | http://hdl.handle.net/11615/78569 | |
dc.description.abstract | [No abstract available] | en |
dc.language.iso | en | en |
dc.source | Journal of Diabetes Investigation | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85127221663&doi=10.1111%2fjdi.13787&partnerID=40&md5=6b16b380b78835a0fef5ab15bedb0cf0 | |
dc.subject | coronavirus spike glycoprotein | en |
dc.subject | covax-19 vaccine | en |
dc.subject | immunoglobulin G | en |
dc.subject | messenger RNA | en |
dc.subject | vaccine | en |
dc.subject | antibody detection | en |
dc.subject | blood sampling | en |
dc.subject | coronavirus disease 2019 | en |
dc.subject | COVID-19 serological testing | en |
dc.subject | diabetes mellitus | en |
dc.subject | disease assessment | en |
dc.subject | glycemic control | en |
dc.subject | Greece | en |
dc.subject | groups by age | en |
dc.subject | hospital admission | en |
dc.subject | hospital patient | en |
dc.subject | hospitalization | en |
dc.subject | human | en |
dc.subject | immune response | en |
dc.subject | laboratory test | en |
dc.subject | lateral flow immunochromatography | en |
dc.subject | Letter | en |
dc.subject | longevity | en |
dc.subject | maintenance therapy | en |
dc.subject | nonhuman | en |
dc.subject | patient coding | en |
dc.subject | patient participation | en |
dc.subject | population structure | en |
dc.subject | sensitivity and specificity | en |
dc.subject | Severe acute respiratory syndrome coronavirus 2 | en |
dc.subject | diabetes mellitus | en |
dc.subject | immunity | en |
dc.subject | prevention and control | en |
dc.subject | COVID-19 | en |
dc.subject | Diabetes Mellitus | en |
dc.subject | Humans | en |
dc.subject | Immunity | en |
dc.subject | SARS-CoV-2 | en |
dc.subject | Vaccines | en |
dc.subject | John Wiley and Sons Inc | en |
dc.title | Immune response to the severe acute respiratory syndrome coronavirus 2 vaccines: Is it sustained in the diabetes population? | en |
dc.type | other | en |